C-C趋化因子配体5及其受体C-C趋化因子配体5辅助受体在胃癌中的研究进展  

Research progress in C-C chemokine ligand 5 and chemokine C-C motif receptor 5 in gastric cancer

作　　者：尹清玲 谢雪晴 田菁菁 卢伟 侯美君 陈训盛 曾丽丽 刘槟 朱远琳 张科 丁杰[2] Yin Qingling;Xie Xueqing;Tian Jingjing;Lu Wei;Hou Meijun;Chen Xunsheng;Zeng Lili;Liu Bing;Zhu Yuanlin;Zhang Ke;Ding Jie(Guizhou University School of Medicine,Guizhou 550025,China;Department of Gastrointestinal Surgery,Guizhou Provincial People’s Hospital,Guizhou 550002,China)

机构地区：[1]贵州大学医学院,贵州550025 [2]贵州省人民医院胃肠外科,贵州550002

出　　处：《中华实验外科杂志》2024年第5期1094-1098,共5页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(81360366、81302169、82360586);贵州省科技计划项目(黔科合基础[2019]1198、黔科合基础[2020]1Z064)。

摘　　要：胃癌是一种常见的恶性肿瘤,其患者晚期预后差,5年生存率低于50%,其发病机制目前尚未清楚.肿瘤微环境(TME)的存在促进了肿瘤细胞增殖、迁移能力及免疫逃逸能力,进而促进肿瘤的发生发展.C-C趋化因子配体5(CCL5)是TME中的一种趋化因子,CCL5与其受体C-C趋化因子配体5辅助受体(CCR5)组成的生物轴在招募肿瘤相关免疫抑制细胞中发挥着积极的作用,已有研究表明该轴与胃癌细胞的生长和转移密切相关.因此,CCL5/CCR5生物轴有望在胃癌的诊断、治疗以及预后方面提供更多依据和指导.本文回顾了CCL5/CCR5生物轴在胃癌发生及发展过程中的作用及相关靶向治疗的研究进展.Gastric cancer is a common malignant tumor with poor prognosis and 5-year survival rate of less than 50%.Its pathogenesis is still unclear.The existence of tumor microenvironment(TME)promoted the proliferation,migration and immune escape ability of tumor cells,thus promoting the occurrence and development of tumors.C-C chemokine ligand 5(CCL5)is a chemokine in the TME.The biological axis composed of CCL5 and its receptor,chemokine C-C motif receptor 5(CCR5),plays an active role in the recruitment of tumor-associated immunosuppressive cells,and has been shown to be closely related to the growth and metastasis of gastric cancer cells.Therefore,the CCL5/CCR5 biological axis is expected to provide more evidence and guidance in the diagnosis,treatment and prognosis of gastric cancer.This article reviews the role of CCL5/CCR5 biological axis in the occurrence and development of gastric cancer and the progress of related targeted therapy.

关 键 词：胃癌 趋化因子配体 肿瘤微环境 

分 类 号：R735.2[医药卫生—肿瘤]